You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.
The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.
The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.
The molecular test developed in collaboration with Self-screen identifies HPV 16 and 18 and concurrently detects the other 13 common high-risk types of HPV infection.
The peer-reviewed study assessed sensitivity rates of HPV testing alone, Pap testing alone, and cotesting with both HPV and Pap tests.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.
The test, which is used to screen for cervical cancer, was previously approved by the agency for use with the Cobas 4800 system.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The biomarker-based test determines women whose human papillomavirus infections are most likely to be associated with cervical pre-cancers.